TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hepatobiliary cancers.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with hepatobiliary cancer.

LEARNING OBJECTIVES

• Recall recently presented clinical trial results with combined anti-PD-L1 antibody and anti-VEGF therapy for patients with hepatocellular carcinoma (HCC) and a high risk of recurrence after curative resection or ablation or those receiving transarterial chemoembolization for unresectable disease, and consider the potential role of these strategies in clinical practice.
• Appreciate available Phase III data with first-line anti-PD-1/PD-L1 antibodies in combination with anti-VEGF or anti-CTLA-4 antibodies for unresectable or metastatic HCC, and discuss how these regimens can be optimally integrated into patient care.
• Discuss the evaluation of immune checkpoint inhibitors as initial therapy for advanced biliary tract cancers (BTCs), and counsel patients about the risks and benefits of these first-line approaches.
• Assess key data sets supporting the FDA approvals of FGFR inhibitors for unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement.
• Evaluate clinical trial findings with HER2-directed therapies for HER2-positive BTCs, and assess the current and potential utility of these treatments for appropriately selected patients.
• Implement a plan of care to recognize and manage side effects and toxicities associated with approved and emerging systemic therapies for hepatobiliary cancers.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of May 2024 to May 2025.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2024/HepatobiliaryCancers/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY 
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. 

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2024/Hepatobiliary/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Blanca Ledezma, MSN, NP, AOCNP
UCLA Santa Monica Hematology/Oncology
Santa Monica, California

Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Lilly.

Stacey Stein, MD
Associate Professor of Medicine
Assistant Medical Director of the Clinical Trials Office
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Advisory Committees: AbbVie Inc, Eisai Inc, Genentech, a member of the Roche Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Merck; Data and Safety Monitoring Boards/Committees: Aethlon Medical Inc, Genentech, a member of the Roche Group.

Amanda K Wagner, APRN-CNP, AOCNP
GI Malignancies
The James Cancer Hospital
The Ohio State University
Columbus, Ohio

No relevant conflicts of interest to disclose.

Mark Yarchoan, MD
Associate Professor of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group; Co-Founder with Equity: Adventris Pharmaceuticals; Research Funding (to Johns Hopkins): Bristol Myers Squibb, Exelixis Inc, Genentech, a member of the Roche Group, Incyte Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Incyte Corporation, and Taiho Oncology Inc.

Release date: May 2024
Expiration date: May 2025

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.